Interest of S100B Protein for Patient Victim of Minor Traumatic Brain Injury and Treated by Antiplatelet

Launched by POITIERS UNIVERSITY HOSPITAL · Dec 17, 2018

Keywords

ClinConnect Summary

This clinical trial is studying the S100B protein to see if it can help doctors determine the risk of serious problems in patients with minor traumatic brain injuries (TBIs) who are also taking antiplatelet medication. Antiplatelet drugs are used to prevent blood clots, but they can affect how the brain heals after an injury. The goal is to see if measuring the level of the S100B protein in the blood can reliably indicate whether a patient is at low risk for complications.

To be eligible for the study, participants must be over 18 years old, have a minor TBI (with a Glasgow Coma Score between 13 and 15), and be taking antiplatelet medication. Patients will have a blood sample taken to check their S100B levels, but their usual medical care will not change, and they will receive a CT scan as recommended for their condition. It’s important to note that certain patients, such as those under 18 or with more severe brain injuries, will not be included in this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18 Years old
• • Minor traumatic brain injury measured by a Glasgow score between 13 and 15
• • Antiplatelet agent therapy
• • Free subject without tutorship or curatorship
• Exclusion Criteria:
• • Age \< 18 years old
• • Glasgow score \<13
• • Traumatic brain injury older than 6 hours
• • Patient without any social security system
• • Patient with renforced protection (tutorship, curatorship, ...)